Maternal and Perinatal Risk Factors for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review

Ilya Querter1, Nele S Pauwels2, Ruth De Bruyne3

  • 1Hepatology Research Unit, Department of Internal Medicine and Pediatrics, Liver Research Center Ghent, Ghent University, Ghent.

Insights

Maternal obesity increases the risk of pediatric nonalcoholic fatty liver disease (NAFLD). Breastfeeding for at least six months may protect children from developing NAFLD, highlighting early life factors in liver health.

Area of Science:

  • Pediatric Gastroenterology and Hepatology
  • Metabolic Health and Disease
  • Public Health and Epidemiology

Background:

  • Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver condition in children.
  • The early life environment significantly influences long-term metabolic health.
  • Understanding risk factors for pediatric NAFLD is crucial for public health interventions.

Purpose of the Study:

  • To investigate the impact of maternal prepregnancy obesity, gestational diabetes, breastfeeding, and birth anthropometrics on pediatric NAFLD development.
  • To identify modifiable risk factors for nonalcoholic fatty liver disease in children and adolescents.

Main Methods:

  • A systematic review and meta-analysis of studies published through August 2020.
  • Inclusion of data from MEDLINE, PubMed Central, EMBASE, and grey literature.
  • Independent review of study selection, data extraction, and quality assessment.

Main Results:

  • Maternal prepregnancy overweight and obesity were identified as significant risk factors for pediatric NAFLD.
  • Breastfeeding, particularly for durations of six months or longer, was associated with a reduced risk of NAFLD, steatohepatitis, and fibrosis.
  • Evidence regarding the impact of (pre)gestational diabetes and birth anthropometrics (preterm birth, small for gestational age) on pediatric NAFLD remains conflicting or unclear.

Conclusions:

  • Maternal prepregnancy overweight and obesity are linked to an increased risk of developing nonalcoholic fatty liver disease in children.
  • Sufficiently long breastfeeding duration (≥6 months) may offer a protective effect against pediatric NAFLD.
  • Early life environmental factors play a critical role in the pathogenesis of pediatric NAFLD.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
71
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
90
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
49
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
72
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
58
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
3.5K